We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

Protagonist Therapeutics (PTGX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its target price boosted by equities researchers at BMO Capital ...

J.P. Morgan analyst Brian Cheng maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report) yesterday and set a price target ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Truist Financial raised their price target on the stock from $60.00 to $76.00.

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra (JNJ-2113), an investigational targeted oral peptide that ...

The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics (PTGX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.